Novel Approaches for the Treatment of Familial Hypercholesterolemia: Current Status and Future Challenges-Reference-Cited by-同舟云学术

Novel Approaches for the Treatment of Familial Hypercholesterolemia: Current Status and Future Challenges

Published:2018-08-01 Issue:8 Volume:25 Page:665-673
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Jiang Long¹,Wang Lu-Ya²,Cheng Xiao-shu¹

Affiliation:

1. Department of Cardiology, the Second Affiliated Hospital of Nanchang University

2. Beijing An Zhen Hospital, Capital Medical University, The Key Laboratory of Remodeling-related Cardiovascular Diseases, Ministry of Education, Beijing Institute of Heart, Lung and Blood Vessel Diseases

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/25/8/25_43372/_pdf

Reference54 articles.

1. 1) Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjaerg-Hansen A, Watts GF, Averna M, Boileau C, Boren J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ and European Atherosclerosis Society Consensus Panel on Familial H: Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J, 2014; 35: 2146-2157

2. 2) Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg-Hansen A and European Atherosclerosis Society Consensus P: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34: 3478-3490a

3. 3) Perez de Isla L, Alonso R, Mata N, Fernandez-Perez C, Muniz O, Diaz-Diaz JL, Saltijeral A, Fuentes-Jimenez F, de Andres R, Zambon D, Piedecausa M, Cepeda JM, Mauri M, Galiana J, Brea A, Sanchez Munoz-Torrero JF, Padro T, Argueso R, Miramontes-Gonzalez JP, Badimon L, Santos RD, Watts GF and Mata P: Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation, 2017; 135: 2133-2144

4. 4) Mabuchi H: Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan. J Atheroscler Thromb, 2017; 24: 189-207

5. 5) Hovingh GK, Goldberg AC and Moriarty PM: Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit. J Clin Lipidol, 2017; 11: 602-616

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ferritin‐based disruptor nanoparticles: A novel strategy to enhance LDL cholesterol clearance via multivalent inhibition of PCSK9–LDL receptor interaction;Protein Science;2024-08-16

2. Dyslipidemia: A Narrative Review on Pharmacotherapy;Pharmaceuticals;2024-02-23

3. Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy;International Journal of Molecular Sciences;2024-01-29

4. Old age as a risk factor for liver diseases: Modern therapeutic approaches;Experimental Gerontology;2023-12

5. Introductory Chapter: RNA Drugs Development and Commercialization;RNA Therapeutics - History, Design, Manufacturing, and Applications;2023-05-24